SCM
AMLX icon

Soleus Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Soleus Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-120,000
Closed -$2.59M – 94
2023
Q2 		$2.59M Buy
120,000
+56,786
+90% +$1.53M 0.29% 64
2023
Q1 		$1.85M Buy
63,214
+12,578
+25% +$437K 0.19% 66
2022
Q4 		$1.87M Sell
50,636
-378,700
-88% -$13.4M 0.27% 60
2022
Q3 		$12.1M Buy
+429,336
New +$10.7M 1.64% 19

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Soleus Capital Management's AMLX Position: Q3 2023 in Review

Soleus Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2023, closing a stake of 120,000 shares — an estimated $2.59M sold.

Soleus Capital Management first reported a position in AMLX in Q3 2022 and held it in 4 quarters. The position peaked at $12.1M in Q3 2022. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

  • Soleus Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 120,000 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $2.59M.
  • Soleus Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Soleus Capital Management's Amylyx Pharmaceuticals position peaked at $12.1M in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.